HIV infection significantly impairs the body’s ability to keep the replication of the hepatitis C virus (HCV) under control when coinfection occurs, says an international group of researchers in an article published in the June 1st... more>

Italian investigators have reported three cases which suggest that treatment with tenofovir (Viread) may increase the risk of liver side-effects caused by efavirenz (Sustiva). The reports are published in the May 11th... more>

The majority of patients with resistance to existing NNRTIs will benefit from treatment with etravirine (Intelence), a new, powerful NNRTI with a high barrier to resistance, according to a UK study published in the May 11th... more>

today's news

• HIV reduces body's ability to control hepatitis C replication
• Does tenofovir increase the risk of efavirenz-associated liver side-effects?
• Nearly all patients with NNRTI resistance could benefit from etravirine, UK analysis shows